IMCCIM Cannabis Corp.
The schedule
- Thu15Oct
Potential regulatory shifts in IMCC's core cannabis markets could offer a macro tailwind.
- Tue9Feb
Q3 earnings will serve as a critical gauge of IMCC's viability heading into 2027.
- Mon15Feb
IMCC faces a probable reverse split to regain compliance with minimum bid price requirements.
- Tue11May
- Tue10Aug
Past
- Tue11Aug
Actual outcome: Bull · $1.87 at outcome
IMCC reported Q2 2026 EPS of -$0.39, exactly matching analyst estimates. The stock reached the $0.13 bull target, supported by the in-line earnings results and a recent $250,000 convertible note financing that provided additional capital.
Q2 results will reveal if IMCC has managed to halt its revenue decline and improve its gross margins.
- Wed15Jul
Actual outcome: Bear
IMCC shares fell 15.7% as the company continued to face severe liquidity constraints and debt servicing pressures. The lack of a non-dilutive funding solution left the market anticipating a highly dilutive equity raise, which weighed heavily on the stock and drove it lower.
IMCC may be forced into a highly dilutive equity offering to maintain operations and service its debt.
- Tue30Jun
Actual outcome: Bear · $0.12 at outcome
IM Cannabis announced a small US$225,000 convertible note financing, highlighting the severity of its ongoing liquidity crisis. The dilutive nature of the financing and the lack of a more substantial debt restructuring or asset sale update disappointed investors, driving the stock down 31.2% to breach the bear floor.
Management is expected to provide an update on debt restructuring or asset sales to address the looming liquidity crisis.
